Evidence map›Paper›PMID 27984697›Full record

ArticleACS chemical neuroscience2017

Delineating Amyloid Plaque Associated Neuronal Sphingolipids in Transgenic Alzheimer's Disease Mice (tgArcSwe) Using MALDI Imaging Mass Spectrometry.

Ibrahim Kaya, Dimitri Brinet, Wojciech Michno, Stina Syvänen, Dag Sehlin, Henrik Zetterberg, Kaj Blennow, Jörg Hanrieder

Open access · greenAbstract read
In one paragraph

Article in ACS chemical neuroscience, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 101 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Ibrahim KayaDepartment of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg , 431 80 Mölndal, Sweden.
Dimitri BrinetDepartment of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg , 431 80 Mölndal, Sweden.
Wojciech MichnoDepartment of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg , 431 80 Mölndal, Sweden.
Stina SyvänenDepartment of Public Health and Caring Sciences, Uppsala University , 752 37 Uppsala, Sweden.
Dag SehlinDepartment of Public Health and Caring Sciences, Uppsala University , 752 37 Uppsala, Sweden.
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg , 431 80 Mölndal, Sweden.
Kaj BlennowDepartment of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg , 431 80 Mölndal, Sweden.
Jörg HanriederDepartment of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg , 431 80 Mölndal, Sweden.ORCID 0000-0001-6059-198X
University of Gothenburg · SESahlgrenska University Hospital · SEUppsala University · SEUniversity College London · GB

Funding

European Research Council 681712
6 · The paper itself

Abstract

The major pathological hallmarks of Alzheimer's disease (AD) are the progressive aggregation and accumulation of beta-amyloid (Aβ) and hyperphosphorylated tau protein into neurotoxic deposits. Aβ aggregation has been suggested as the critical early inducer, driving the disease progression. However, the factors that promote neurotoxic Aβ aggregation remain elusive. Imaging mass spectrometry (IMS) is a powerful technique to comprehensively elucidate the spatial distribution patterns of lipids, peptides, and proteins in biological tissue sections. In the present study, matrix-assisted laser desorption/ionization (MALDI) mass spectrometry (MS)-based imaging was used on transgenic Alzheimer's disease mouse (tgArcSwe) brain tissue to investigate the sphingolipid microenvironment of individual Aβ plaques and elucidate plaque-associated sphingolipid alterations. Multivariate data analysis was used to interrogate the IMS data for identifying pathologically relevant, anatomical features based on their lipid chemical profile. This approach revealed sphingolipid species that distinctly located to cortical and hippocampal deposits, whose Aβ identity was further verified using fluorescent amyloid staining and immunohistochemistry. Subsequent multivariate statistical analysis of the spectral data revealed significant localization of gangliosides and ceramides species to Aβ positive plaques, which was accompanied by distinct local reduction of sulfatides. These plaque-associated changes in sphingolipid levels implicate a functional role of sphingolipid metabolism in Aβ plaque pathology and AD pathogenesis. Taken together, the presented data highlight the potential of imaging mass spectrometry as a powerful approach for probing Aβ plaque-associated lipid changes underlying AD pathology.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAnimalsDisease Models, AnimalFemaleHumansMaleMiceMice, TransgenicMultivariate AnalysisMutationPlaque, AmyloidSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationSphingolipidsAmyloid beta-PeptidesAmyloid beta-Protein PrecursorSphingolipidsAlzheimer’s diseaseamyloid-β plaque pathologyMALDI imaging mass spectrometrysphingolipidstgArcSwe

Identifiers

PMID27984697
PMCPMC5314428
OpenAlexW2560924453

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.